Preclinical Characterization of MIN-301, a Neuregulin-1 Fragment, as a Potential Disease-Modifying Therapy for Parkinson's Disease

被引：0
|
作者：
Noel, Nadine [1 ]
Werner, Sandra [1 ]
Lowe, David [1 ]
Detke, Michael [1 ]
Luthringer, Remy [1 ]
机构：
[1] Indiana Univ, Carmel, IN USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2015年 / 40卷
关键词：
Parkinson's disease; Neuregulin; 6-OHDA; MPTP;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W138
引用
收藏
页码：S529 / S530
页数：2
相关论文
共 50 条
  • [1] Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease
    Carlsson, Thomas
    Schindler, Friederike R.
    Hoellerhage, Matthias
    Depboylu, Candan
    Arias-Carrion, Oscar
    Schnurrbusch, Stefan
    Roesler, Thomas W.
    Wozny, Wojciech
    Schwall, Gerhard P.
    Groebe, Karlfried
    Oertel, Wolfgang H.
    Brundin, Patrik
    Schrattenholz, Andre
    Hoeglinger, Guenter U.
    JOURNAL OF NEUROCHEMISTRY, 2011, 117 (06) : 1066 - 1074
  • [2] Disease-Modifying Drugs in Parkinson’s Disease
    Ariane Park
    Mark Stacy
    Drugs, 2015, 75 : 2065 - 2071
  • [3] Disease-modifying drugs and Parkinson's disease
    Allain, Herve
    Bentue-Ferrer, Daniele
    Akwa, Yvette
    PROGRESS IN NEUROBIOLOGY, 2008, 84 (01) : 25 - 39
  • [4] Mitochondrial therapy for Parkinson's disease: Neuroprotective pharmaconutrition may be disease-modifying
    Kones, Richard
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2010, 2 : 185 - 198
  • [5] Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress
    Carroll, Camille B.
    Wyse, Richard K. H.
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (04) : 545 - 568
  • [6] Mechanism of Mesenchymal Stem Cells as a Multitarget Disease-Modifying Therapy for Parkinson's Disease
    Unnisa, Aziz
    Dua, Kamal
    Kamal, Mohammad Amjad
    CURRENT NEUROPHARMACOLOGY, 2023, 21 (04) : 988 - 1000
  • [7] Disease-modifying targets and strategies for Alzheimer's disease and Parkinson's disease
    Gao, Xiaoya
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [8] Challenges to the development of disease-modifying therapies in Parkinson's disease
    Schapira, A. H. V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 16 - 21
  • [9] Level of plasma neuregulin-1 SMDF is reduced in patients with idiopathic Parkinson's disease
    Hama, Yuka
    Yabe, Ichiro
    Wakabayashi, Koichi
    Kano, Takahiro
    Hirotani, Makoto
    Iwakura, Yuriko
    Utsumi, Jun
    Sasaki, Hidenao
    NEUROSCIENCE LETTERS, 2015, 587 : 17 - 21
  • [10] The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson's Disease
    Neha
    Mazahir, Iqra
    Khan, Sara Akhtar
    Kaushik, Pooja
    Parvez, Suhel
    MOLECULAR NEUROBIOLOGY, 2024, 61 (10) : 8086 - 8103
12345